Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Open access
Krejcik, Jakub, Frerichs, Kris A., Nijhof, Inger S., van Kessel, Berris, van Velzen, Jeroen F., Bloem, Andries C., Broekmans, Marloes E.C., Zweegman, Sonja, van Meerloo, Johan, Musters, René J.P., Poddighe, Pino J., Groen, Richard W.J., Chiu, Christopher, Plesner, Torben, Lokhorst, Henk M., Sasser, A. Kate, Mutis, Tuna, van de Donk, Niels W.C.J. · 2017 · Clinical Cancer Research

Abstract

Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduction. Experimental Design: We evaluated the effect of daratumumab alone or in combination with lenalidomide-dexamethasone, on CD38 levels of multiple myeloma cells and nontumor immune cells in the GEN501 study (daratumumab monotherapy) and the GEN503 study (daratumumab combined with lenalidomide-dexamethasone). In vitro assays were also performed. Results: In both trials, daratumumab reduced CD38 expression on multiple myeloma cells within hours after starting the first infusion, regardless of depth and duration of the response. In addition, CD38 expression on nontumor immune cells, including natural killer cells, T cells, B cells, and monocytes, was also reduced irrespective of alterations in their absolute numbers during therapy. In-depth analyses revealed that CD38 levels of multiple myeloma cells were only reduced in the presence of complement or effector cells, suggesting that the rapid elimination of CD38high multiple myeloma cells can contribute to CD38 reduction. In addition, we discovered that daratumumab–CD38 complexes and accompanying cell membrane were actively transferred from multiple myeloma cells to monocytes and granulocytes. This process of trogocytosis was also associated with reduced surface levels of some other membrane proteins, including CD49d, CD56, and CD138. Conclusions: Daratumumab rapidly reduced CD38 expression levels, at least in part, through trogocytosis. Importantly, all these effects also occurred in patients with deep and durable responses, thus excluding CD38 reduction alone as a mechanism of daratumumab resistance. The trials were registered at www.clinicaltrials.gov as NCT00574288 (GEN501) and NCT1615029 (GEN503). Clin Cancer Res; 23(24); 7498–511. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2027

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 176

Metadata

Authors
Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., Poddighe, P. J., Groen, R. W. J., Chiu, C., Plesner, T., Lokhorst, H. M., Sasser, A. K., Mutis, T., & van de Donk, N. W. C. J.
Venue
Clinical Cancer Research
Published
2017-12-14
Volume
23
Issue
24
Pages
7498-7511
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2764340845
Cited by
176
References
6
FWCI
12.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2027
The paper
Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., Poddighe, P. J., Groen, R. W. J., Chiu, C., Plesner, T., Lokhorst, H. M., Sasser, A. K., Mutis, T., & van de Donk, N. W. C. J. (2017). Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.